Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 6.92Syncom Formulations exhibits a mixed financial profile. The company demonstrates strong solvency and growth, indicating a solid financial foundation and promising expansion. Profitability is also a notable strength, driven by healthy margins and returns on capital. However, efficiency and financial metrics suggest areas needing attention. While liquidity is adequate, there's room to optimize cash management. The company's revenue, operating profit, and EPS are growing significantly. Syncom Formulations maintains a strong position with zero debt. While fixed asset and capital turnover are low, inventory management is efficient. The company shows potential for continued growth and profitability, but improvements in operational efficiency and financial management are crucial for sustained success.
Health Score : 6.92Syncom Formulations exhibits a mixed financial profile. The company demonstrates strong solvency and growth, indicating a solid financial foundation and promising expansion. Profitability is also a notable strength, driven by healthy margins and returns on capital. However, efficiency and financial metrics suggest areas needing attention. While liquidity is adequate, there's room to optimize cash management. The company's revenue, operating profit, and EPS are growing significantly. Syncom Formulations maintains a strong position with zero debt. While fixed asset and capital turnover are low, inventory management is efficient. The company shows potential for continued growth and profitability, but improvements in operational efficiency and financial management are crucial for sustained success.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
24.78
Industry Median
30.91
Small Cap Median
28.64
P/E RATIO
24.78
P/B RATIO
4.55
Industry Median
3.69
Small Cap Median
3.11
P/S RATIO
3.78
Industry Median
3.74
Small Cap Median
3.02
Others
PEG RATIO
0.53
EV/EBITDA RATIO
16.88
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹20.07 as on Sep 1, 2026.
Growth Score : 10.00The company exhibits excellent growth across all measured metrics. This signals a strong upward trajectory in its business operations and financial performance. The company's revenue, operating profit, and EPS are growing significantly. Such robust growth is a positive indicator of the company's competitive positioning and ability to capitalize on market opportunities. Maintaining this growth momentum is crucial for long-term success.
Revenue Growth RateExcellentOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue Growth Rate | 2.78 | 18.02 | 76.72 | 5.62 |
| Operating Profit Growth Rate | 0 | 50 | 80 | 42.59 |
| Earnings Per Share (EPS) Growth | -8.7 | 28.57 | 96.3 | 52.83 |
| Asset Growth Rate | 22.73 | 7.14 | 1.98 | 29.3 |
| Net Income Growth Rate | 0 | 25 | 96 | 55.1 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Jagsonpal Pharmaceuticals Ltd | 8.51 | 37.27 | Overvalued | 58.00 | 6.54 | 43.00 |
| 2 | Amrutanjan Health Care Ltd | 8.25 | 70.69 | Highly Overvalued | 31.00 | 20.03 | 21.00 |
| 3 | Accent Microcell Ltd | 7.96 | 24.25 | Neutral | 57.00 | 18.28 | 44.00 |
| 4 | Windlas Biotech Ltd | 7.52 | 32.03 | Neutral | 105.00 | 32.19 | 66.00 |
| 5 | Lincoln Pharmaceuticals Ltd | 7.31 | 13.89 | Neutral | 98.00 | 43.88 | 88.00 |
| 6 | Kilitch Drugs (India) Ltd | 7.12 | 22.83 | Neutral | 37.00 | 9.27 | 30.00 |
| 7 | NGL Fine Chem Ltd | 6.98 | 34.11 | Neutral | 73.00 | 67.39 | 48.00 |
| 8 | Syncom Formulations (India) Ltd | 6.92 | 24.78 | Neutral | 77.00 | 0.81 | 76.00 |
| 9 | Sakar Healthcare Ltd | 6.89 | 70.49 | Highly Overvalued | 69.00 | 13.70 | 30.00 |
| 10 | Kopran Ltd | 6.60 | 40.82 | Undervalued | 62.00 | 6.30 | 26.00 |
| 11 | Hester Biosciences Ltd | 6.54 | 33.64 | Neutral | 87.00 | 61.24 | 57.00 |
| 12 | Sigachi Industries Ltd | 6.49 | -14.82 | Neutral | 54.00 | -2.08 | -83.00 |
| 13 | Remus Pharmaceuticals Ltd | 5.31 | 27.61 | Neutral | 57.00 | 20.97 | 46.00 |
| 14 | Ind-Swift Laboratories Ltd | 4.95 | 77.18 | Neutral | 45.00 | 4.89 | 41.00 |
| 15 | Venus Remedies Ltd | 4.83 | 23.37 | Neutral | 147.00 | 74.30 | 103.00 |
| 16 | Wanbury Ltd | 4.65 | 27.30 | Neutral | 88.00 | 15.98 | 43.00 |
| 17 | Solara Active Pharma Sciences Ltd | 4.34 | -313.88 | Neutral | 187.00 | -1.50 | -7.00 |
| 18 | NOVARTIND | N/A | N/A | N/A | N/A | N/A | N/A |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
Syncom Formulations (India) Ltd is a pharmaceutical manufacturer based in Indore, specializing in a diverse range of pharmaceutical formulations. The company produces allopathic, ayurvedic, and nutraceutical products across various dosage forms like tablets, capsules, and liquids, serving both domestic and international markets.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Syncom Formulations (India) Ltd's P/E ratio (TTM) is 24.78, compared to the industry median of 30.91 and large cap median of 28.64.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Syncom Formulations (India) Ltd's P/B ratio is 4.55, compared to the industry median of 3.69 and large cap median of 3.11.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Syncom Formulations (India) Ltd's P/S ratio is 3.78, compared to the industry median of 3.74 and large cap median of 3.02.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Syncom Formulations (India) Ltd's PEG ratio is 0.53.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Syncom Formulations (India) Ltd's EV/EBITDA ratio is 16.88.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Syncom Formulations (India) Ltd's ROE is 18.31%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Syncom Formulations (India) Ltd's ROA is 14.42%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Syncom Formulations (India) Ltd's ROCE is 27%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Syncom Formulations (India) Ltd's operating margin is 15.75%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Syncom Formulations (India) Ltd's net margin is 15.54%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Syncom Formulations (India) Ltd's current ratio is 2.03.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Syncom Formulations (India) Ltd's debt-to-equity ratio is 0.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Syncom Formulations (India) Ltd's interest coverage ratio is 102.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Syncom Formulations (India) Ltd's DPS is ₹0.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Syncom Formulations (India) Ltd's EPS is 52.83.
(Source line: "Ratios as of 25 Sept 2026, based on last traded price of ₹20.07. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1982
Headquarters: Indore, Madhya Pradesh
Core Offerings: Tablets, Capsules, Oral Liquids, Injectables, Ayurvedic & Herbal Products
Stock Listing: NSE (SYNCOMF), BSE (524470)
Promoter: Bhardwaj Group / Mr. Jagdish Prasad Bhardwaj
Syncom Formulations (India) Ltd was incorporated in 1982. Commercial production of pharmaceutical formulations commenced in 1986 at its Indore facility. The company converted into a Public Limited Company in 1992 and made its public issue in 1994 to expand operations. Over the decades, Syncom has continuously expanded its product portfolio and market presence, focusing on both domestic and export markets.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Allopathic Formulations | N/A | Operating Profit |
| Ayurvedic & Herbal Products | N/A | Operating Profit |
| Nutraceuticals | N/A | Operating Profit |
Allopathic Formulations: Manufacturing and marketing of modern medicines including tablets, capsules, oral liquids, injections, and ointments across various therapeutic areas.
Ayurvedic & Herbal Products: Production and sale of traditional Indian medicinal preparations and herbal supplements.
Nutraceuticals: Focus on dietary supplements, vitamins, and health-enhancing products.
Mr. Jagdish Prasad Bhardwaj (Chairman & Managing Director): Founder of the company with extensive experience in the pharmaceutical industry, providing strategic leadership. Mr. Ajay Kumar Bhardwaj (Joint Managing Director): Oversees various operational aspects and plays a key role in the company's growth and expansion.
No major subsidiaries reported.
Stock Split (1:10) and Bonus Issue (1:1) on September 1, 2022.
The Syncom Formulations (India) Ltd share price today is ₹20.07 on NSE (SYNCOMF), as of 26 Sept 2026.
As of 25 Sept 2026, Syncom Formulations (India) Ltd share price is ₹20.07, with previous close ₹20.07. Today's range is ₹20.07 to ₹20.07. The 52-week range is ₹10.21 to ₹22.59.
As of today, Syncom Formulations (India) Ltd's market cap is ₹1,846.64 crore (Small Cap).
Syncom Formulations (India) Ltd's current P/E ratio is 24.78, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 32.
Syncom Formulations (India) Ltd's current P/B ratio is 4.55.
Syncom Formulations (India) Ltd's current dividend yield is N/A. Last dividend of ₹0.05 per share was declared on 14-Aug-2023.
Syncom Formulations (India) Ltd's EPS (TTM) is ₹52.83.
Syncom Formulations (India) Ltd is a pharmaceutical manufacturer based in Indore, specializing in a diverse range of pharmaceutical formulations. The company produces allopathic, ayurvedic, and nutraceutical products across various dosage forms like tablets, capsules, and liquids, serving both domestic and international markets.
Syncom Formulations (India) Ltd is promoted by Bhardwaj Group / Mr. Jagdish Prasad Bhardwaj, holding 50.57% as of 25 Sept 2026.
Syncom Formulations (India) Ltd is listed on NSE (SYNCOMF) and BSE (524470). Its next quarterly results are expected on August 2024.
Adjusted Earnings Per Share (Adjusted EPS)
